PRTA vs. DVAX, URGN, AKBA, PBYI, MRNS, NUVL, ALPN, ALKS, CRNX, and PRGO
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Dynavax Technologies (DVAX), UroGen Pharma (URGN), Akebia Therapeutics (AKBA), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Crinetics Pharmaceuticals (CRNX), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Dynavax Technologies (NASDAQ:DVAX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Dynavax Technologies has a net margin of 3.91% compared to Dynavax Technologies' net margin of -193.17%. Prothena's return on equity of 1.52% beat Dynavax Technologies' return on equity.
Dynavax Technologies presently has a consensus price target of $25.33, indicating a potential upside of 110.06%. Prothena has a consensus price target of $67.00, indicating a potential upside of 217.08%. Given Dynavax Technologies' higher possible upside, analysts plainly believe Prothena is more favorable than Dynavax Technologies.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 28.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Dynavax Technologies has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.
In the previous week, Dynavax Technologies had 3 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Dynavax Technologies and 4 mentions for Prothena. Prothena's average media sentiment score of 1.45 beat Dynavax Technologies' score of 0.63 indicating that Dynavax Technologies is being referred to more favorably in the media.
Dynavax Technologies has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Prothena received 133 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.67% of users gave Prothena an outperform vote while only 65.77% of users gave Dynavax Technologies an outperform vote.
Summary
Dynavax Technologies beats Prothena on 11 of the 18 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
